First Online: 23 December 2014
Change Date: 19 January 2015
Change Type: Correction
Change Details: In the version of this article that was originally published, the targeted epitope of lebrikizumab was listed as "IL‑4Rα" in Table 1 but this should be "IL‑13 (IL‑4Rα‑binding epitope)”. Also, for the main effects of lebrikizumab in human asthma trials, the citation of reference 44 should be reference 48. The author apologizes for these errors, which have now been corrected online.
: The author is a named inventor on a patent application for periostin as a biomarker in asthma. He has consulted for Amgen, Merck, Regeneron, Boehringer Ingelheim and MedImmune.